
Preclinical CRO Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has entered into a definitive agreement to acquire Celsis International Ltd. for $212 million in cash, subject
Lorem ipsum dolor sit amet, consectetur adipiscing elit. In in lorem sit amet ligula feugiat vulputate vel vitae quam. Cras posuere imperdiet lorem, in aliquam urn
Preclinical CRO Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has entered into a definitive agreement to acquire Celsis International Ltd. for $212 million in cash, subject
+44 141 248 2026
Recent Comments